Skip to main content

Table 3 Observed infield acute and late severe (≥ grade 3) toxicity, graded by use of CTCAE v4.03

From: Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the ‘TOaSTT’ database

Patient (n) Toxicity Grade Location SRT Treated metastases (n) Treatment dose (Gy/fx) Concurrent therapy Start of concurrent therapy Systemic therapy paused during SRT
Acute infield toxicity
 1 Headache 3 Brain 3 24 Gy/1fx 100% Isodose) Nivolumab 8 days after SRT
 2 Headache 3 Brain 1 20 Gy/1fx (80% Isodose) Bevacizumab 365 days before SRT No
 3 Headache 3 Brain 2 20 Gy/1fx (80% Isodose) Nivolumab 52 days before SRT No
Gait disturbance 3
 4 Headache 4 Brain 3 20 Gy/1fx (80% Isodose) Nivolumab 11 days after SRT
Nausea 3
 5 Dyspnea 3 Lung 1 7 Gy/5fx (65% Isodose) Gefitinib 503 days before SRT No
 6 Thromboembolic event 3 Brain 1 20 Gy/1fx (80% Isodose) Osimertinib 98 days before SRT No
Late infield toxicity
 7 Radionecrosis 3 Brain 5 20 Gy/1fx (80% Isodose) Afatinib 22 days before SRT No
Nausea 3
Hemiparesis 4
 8 Weight loss 3 Lung 1 7 Gy/5fx (65% Isodose) Erlotinib 575 days before SRT 4 days